Although both MET gene amplification and HGF treatment has been shown to induce gefitinib resistance in lung cancers with EGFR mutations, ErbB3 transactivation is involved only in MET amplification but not in HGF-induced resistance [25]. The gene discussed is MET; the disease is lung carcinoma.